

Wednesday, 19 May 2021

SATISFACTION OF CONDITIONS FOR CONDITIONAL MARKET

Australian Clinical Labs Limited (ASX: ACL) (**ACL** or **Company**) advises that the conditions for the conditional market under the prospectus lodged by ACL and ACL SaleCo Limited (**SaleCo**) with the Australian Securities and Investments Commission on Wednesday, 28 April 2021 (**Prospectus**) have been satisfied, namely:

- settlement under the Underwriting Agreement; and
- that the Company has issued New Shares and SaleCo has transferred existing Shares to successful Applicants under the Offer.

Shares will trade on the ASX on a normal settlement basis from 10:00am (Sydney time) on Wednesday, 19 May 2021.

ACL confirms that dispatch of holding statements will take place on Thursday, 20 May 2021.

Capitalised terms used, but not been otherwise defined, have the meaning given to them in the Prospectus.

– ENDS –

This announcement was authorised for release to ASX by Eleanor Padman, Company Secretary. For further information regarding this announcement, please contact:

Investors

Eleanor Padman
Company Secretary
Email: Eleanor.Padman@clinicallabs.com.au
Phone: +61 422 002 918

Media

Joe Geran
National Marketing Director
Email: Joe.Geran@clinicallabs.com.au
Phone: +61 499 900 967

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our 86 NATA accredited laboratories perform over 8 million episodes each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.